Gastrointestinal Stromal Tumors Gist clinical trials

Explore recruiting gastrointestinal stromal tumors gist clinical trials.

Recruiting gastrointestinal stromal tumors gist studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gastrointestinal Stromal Tumors Gist trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)

France, Spain, Netherlands, Germany, Belgium, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase II, single arm Study of avelumab in combination with Axitinib in Patients with unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST

Italy, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib

Spain, Netherlands, Norway, Italy, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

Spain, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

ATEZOGIST – A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib resumption alone in patients with unresectable advanced gastrointestinal stromal tumors (GIST) after failure of standard treatments

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Gastrointestinal Stromal Tumors Gist trials by city

Gastrointestinal Stromal Tumors Gist in Toronto Gastrointestinal Stromal Tumors Gist in Vancouver Gastrointestinal Stromal Tumors Gist in Montreal Gastrointestinal Stromal Tumors Gist in Calgary Gastrointestinal Stromal Tumors Gist in Edmonton Gastrointestinal Stromal Tumors Gist in Ottawa Gastrointestinal Stromal Tumors Gist in Winnipeg Gastrointestinal Stromal Tumors Gist in Quebec City Gastrointestinal Stromal Tumors Gist in Hamilton Gastrointestinal Stromal Tumors Gist in Kitchener Gastrointestinal Stromal Tumors Gist in London Gastrointestinal Stromal Tumors Gist in Halifax Gastrointestinal Stromal Tumors Gist in New York Gastrointestinal Stromal Tumors Gist in Los Angeles Gastrointestinal Stromal Tumors Gist in Chicago Gastrointestinal Stromal Tumors Gist in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease